Keyword
Quick search:
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Market Assessment of Glatiramer Acetate Industry: Growth Drivers by Top Players like Teva, NATCO Pharma, Mylan, Novartis, HYBIO,, and more | Affluence – Test & Measurement
2 Growth Prospects of Glatiramer Market: Business Outlook 2021-2026 by Teva, NATCO Pharma, Mylan, Novartis, HYBIO,, and more | Affluence – Test & Measurement
3 Latest Research Report On Glatiramer Market 2021. – Brockville Observer
4 Glatiramer Acetate Market Size 2021 by Product Sales, Revenue, Price, Market Share, Growth Opportunity and Forecast to 2024 Research Report I Top key players- Teva, NATCO Pharma, Mylan, Novartis – Clark County Blog
5 MS Therapies That Deplete B-cells Appear to Work Against COVID...
6 Advances in the pharmacological treatment of rare multiple sclerosis variants
7 Federal Court decision regarding glatiramer acetate finds one patent obvious and another valid and infringed
8 MS tingling patterns: What to know and how to cope
9 “RoAD” Score Predicts Prognosis in Relapsing-Remitting Multiple Sclerosis
10 B-Cell Depletion May Indicate Reduced COVID-19 Antibody Response Among Patients With MS
11 Mapi Pharma Presents Glatiramer Acetate Depot (GA Depot) Results at the 8th Joint ACTRIMS-ECTRIMS Meeting MSVirtual2020
12 Multiple Sclerosis (MS) Drugs Market Will Reflect Significant Growth Prospects of US$ Mn during 2021-2026 with Major Key Player: Bayer AG, Bayhill Therapeutics, Biogen Idec, Cinnagen, Daiichi Sankyo, etc – KSU | The Sentinel Newspaper
13 Global Multiple Sclerosis Therapies Market (2021) to Witness Huge Growth by 2026 | ABBVIE INC., BAYER AG., BIOGEN, BRISTOL-MYERS SQUIBB COMPANY, F. HOFFMANN-LA ROCHE LTD. – The Courier
14 Copaxone: Side effects, cost, how to take, uses, and more
15 Mapi Hits Milestone For Viatris-Partnered Long-Acting Glatiramer
16 Teva dips as it reports downturn on 1st-qtr sales and earnings
17 Gilenya Increases Infection Risk in MS Patients, Clinical Data Suggest
18 Mandatory Biosimilar Switching Pays Off for Canada
19 Mapi Pharma and Mylan Strengthen Partnership to Develop and
20 Federal Court Decision Regarding Glatiramer Acetate Finds One Patent Obvious And Another Valid And Infringed
21 MS Society Releases Guidance on DMT Dosing Modifications for COVID-19 Vaccination
22 Tecfidera May Be Effective Option for Relapsing MS Patients Who...
23 Baseline patient characteristics, MS severity impact COVID-19 outcomes
24 Mapi Pharma engages CRO PRA Health for multiple sclerosis trial
25 Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injection) at European Academy of Neurology Congress
26 Calculated Treatment Response Score May Help Choose Between MS Therapies
27 Fingolimod vs Glatiramer Acetate in RRMS: We Have a Winner
28 Antitrust: Commission opens formal investigation: Teva
29 Despite New Generic, MS Drug Costs Nearly Triple in 7 Years
30 Impact of disease‐modifying drugs on the severity of COVID‐19 infection in multiple sclerosis patients
31 Interferon-beta Versus Glatiramer Acetate as Initial Treatment for Multiple Sclerosis: Long-term Follow-up
32 Phase 3 Trial of GA Depot as Monthly Relapsing MS Therapy...
33 Glatiramer acetate (Copaxone) therapy may alter B cell function in multiple sclerosis
34 AbbVie CEO Is on Deck as Antitrust Hearings Heat Up May 3rd 2021 By Tony Hagen
35 Sandoz Slashes Glatiramer Price In US :: Generics Bulletin
36 Teva Calls on FDA to Make Copaxone a Biologic as Part of March Transition
37 Copaxone for Multiple Sclerosis | Side Effects | MS News Today
38 Beyond “pay-for-delay” – the EU-Commission’s investigation into patent filing practices and communication measures
39 Drug to Biologic Transition: Is Purple The New Orange?
40 Global Multiple Sclerosis Therapies Report 2020-2025
41 Impact of the COVID‐19 pandemic on access to healthcare services amongst patients with multiple sclerosis in the Lazio region, Italy
42 Immunotherapies improve long-term disability outcomes in MS
43 Generic Version Of Pricey MS Treatment Didn't Reduce Drug Costs Much For Patients : Shots
44 Mylan Announces US FDA Approval of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and May Be Eligible for 180-Day Exclusivity
45 US Multiple Sclerosis Drugs size, share, 2021-2027: Emerging Trends, Market Opportunities, Future plans, Type and Application – Top players are F. Hoffmann-La, Novartis AG, Roche Ltd, Biogen discussed in a new market research report
46 Glatiramer Acetate for MS Appears Safe Throughout Pregnancy
47 Phase 3 Trial of GA Depot for Relapsing MS Advances With $20M Support
48 Glatopa Shows Efficacy Similar to Copaxone, Study in Real-world...
49 Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone® at American Academy of Neurology 70th Annual Meeting
50 Teva Tries to Block a Rival by Forcing It Through the Biosimilar Application Process
51 Alvogen Obtains First Approval for Glatiramer Acetate 40 mg/mL in Europe
52 Copaxone 40mg/mL (glatiramer acetate) Drug / Medicine Information
53 Teva fails to reclassify MS drug to thwart generics
54 Glatiramer acetate found to fight multi-resistant bacteria
55 Pediatric MS and Body Weight: The Connection
56 Mapi Pharma Provides Enrollment Update in Phase III GA Depot Clinical Trial
57 EC nod for Mylan merger with Upjohn; Copaxone patent win
58 Interferons Superior to Glatiramer Acetate, and Tysabri More...
59 RRMS Safely, Effectively Treated with GTR, Generic Form of Copaxone, Study Says
60 Momenta Pharmaceuticals Announces FDA Approval and Launch of Glatopa® (glatiramer acetate injection) 40 mg/mL
61 Mylan Brings Critical Access to the Multiple Sclerosis Community by Launching a More Affordable Treatment Option Through a First Generic to Tecfidera®
62 US sues Teva over Copaxone co-pay assistance scheme
63 Sigma-Aldrich hit with $9M fine for misleading info during Merck KGaA merger
64 drug monograph Copaxone subcutaneous: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing
65 Copaxone Legal Fight May Finally Be Over As Court Finds The MS Treatment Is Not A Biologic
66 EC launches Teva antitrust investigation | 2021-03-04
67 35% of Newly Diagnosed Patients Given DMT in Follow-up Years, US...
68 MS Medicine Copaxone May Have Benefits in Parkinson's Disease...
69 Is Copaxone for Multiple Sclerosis Right for You?
70 New Findings on How Glatiramer Acetate Works for Multiple Sclerosis
71 Herpes Zoster Infection With MS Treatment Higher in Women?
72 Glatect for RRMS, Similar to Copaxone, Now on Health Plans of 5 Canadian Provinces
73 First Relapsing MS Patient Enrolled in Phase 3 Trial of Mapi...
74 Older Age at DMT Discontinuation Linked to Sustained NEDA in CIS...
75 Mylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma
76 Mapi Pharma Presents Phase II Extension Results of Glatiramer Acetate Depot (GA Depot) at ECTRIMS 2018 in Berlin
77 First time EU Commission pursues case relating to divisional patent filing and litigation strategies
78 Momenta Pharmaceuticals Announces Positive Outcome for Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer
79 Clinical Challenges: Obesity and MS | MedPage Today
80 Risk of Serious Infection for Patients With MS Varies Depending on Treatment
81 Clinical Challenges: MS and Pregnancy | MedPage Today
82 Mylan Launching Tecfidera Generic for Relapsing MS in the US
83 Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe
84 Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE® (glatiramer acetate injection) 40mg/mL
85 Multiple Sclerosis: What Does Medicare Cover?
86 FDA approves Glatopa a generic option for relapsing forms of MS
87 Cost of MS Drugs Nearly Tripled
88 First Generic Version of Copaxone Approved by FDA to Treat...
89 What's the Latest on the Link Between MS and Your Gut?
90 Mavenclad Effectively Lowers Relapse Rates, Study Comparing DMTs Finds
91 Urinary Tract Infection in Multiple Sclerosis: Risk, Diagnosis, and Management
92 Teva faces EU antitrust probe over MS drug Copaxone
93 COVID-19 May Not Be Severe in MS Patients, Early Data from Italy...
94 The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients
95 #AANAM
96 The Unusual Discovery of Commonly Prescribed Medications: Part 4
97 Industrial X-Ray Or CT Market Trends, Top Industry Trends & Opportunities, Demand, Competition Analysis and Forecast to 2025 | General Electric, Agfa Gevaert, Fujifilm Corporation, Nikon Corporation, Shimadzu Corporation – Brockville Observer
98 Covid-19 vaccine and MS: Your questions answered
99 Invalidity Of Copaxone Patents Supported By Statements To FDA
100 Ocrevus Use Rises for New RRMS Patients, Drops Among PPMS Patients